Platform/Research Tool

for BIO 2024
Search text
Active Filters
Assay
11 results
(0.04 seconds)
This technology is an advanced in vitro assay leveraging false fluorescent neurotransmitters (FFNs) to detect and quantify neurotransmitter leakage from synaptic vesicles, offering a dynamic and high-throughput method with implications for understanding neurological diseases and therapeutic developments.
The Technology: Real-time assay for neurotransmitter leakage using fluorescent analogues.
Unmet Need: Assay for patient-specific prediction of cancer progression.
As a result, there is a significant unmet need for an off-the-shelf, practical, and non-invasive assay to evaluate metastatic potential for a given patient and to predict cancer progression, potential for relapse, and response to therapeutics.
The Technology: Off-the-shelf, non-invasive assay for prediction of cancer metastasis.
The Technology: Cell-type specific, adaptable assay for covalently linking proteins in vivo.
There are currently no assay platforms available that enable direct covalent bonding of two peptides in vivo with cell type-specificity without interfering with native protein structure, localization, or function.
The most common method to model wound healing in-situ is the “scratch assay”, in which a cell monolayer is divided with a scratched line and allowed to migrate and fill the space.
More accurately mimics the wound healing process compared to classical scratch assays.
While current methods offer high throughput testing, these assays do not accurately capture all four stages of wound healing; therefore, more comprehensive high throughput models are needed to study wound healing and evaluate potential therapies to improve healing response.
Unmet Need: Affordable, noninvasive diagnostic assay to detect cognitive impairments.
The currently available diagnostic assays remain invasive, costly and are unable to detect early stages of disease.
Applications: Diagnostic assays for mild cognitive impairment, Alzheimer’s disease, and related dementias.
This technology is an assay that utilizes mRNA display technology for high-throughput proteomic analysis by linking expressed proteins to their corresponding mRNA sequences.
This technology predicts a patient’s risk of developing primary graft dysfunction (PGD) after a heart transplant by measuring levels of exosome proteins such as kallikrein (KLKB1), to improve risk stratification, organ allocation, and post-operative care.
    • Tags
      • 23
        High-throughput screening
      • 11
        Assay
      • 8
        Protein
      • 6
        Biomarker
      • 6
        Gene expression
      • Add ...
    • Categories
      • 11
        Biology
      • 10
        Branches of biology
      • 6
        Anatomy
      • 9
        Biotechnology
      • 3
        Bioinformatics
      • Add ...
    • Inventors
      • 2
        Gordana Vunjak-Novakovic
      • 1
        Barry Fine
      • 1
        Binsheng Zhao
      • 1
        Bohao Liu
      • 1
        Bryan Wang
      • Add ...
    • Manager
      • 3
        Kristin Neuman
      • 3
        Sara Gusik
      • 2
        Cynthia Lang
      • 2
        Joan Martinez
      • 1
        Jerry Kokoshka
      • Add ...
    • Departments
      • 3
        Biomedical Engineering
      • 2
        Systems Biology
      • 1
        Biochemistry
      • 1
        Biochemistry & Molecular Biophysics
      • 1
        Biochemistry & Molecular Biophysics, Zuckerman Institute
      • Add ...
    • Divisions
      • 5
        Columbia University Medical Center (CUMC)
      • 3
        Fu Foundation School of Engineering and Applied Science (SEAS)
      • 2
        Mailman School Of Public Health (MSPH)
      • 1
        College of Physicians and Surgeons (CUMC)
      • 1
        Columbia University Medical Center
      • Add ...
    • Reference Number
      • Add ...
    • Release Date
This site uses cookies to deliver a better user experience. Learn more.